CGP 25454A

Drug Profile

CGP 25454A

Latest Information Update: 29 Sep 2000

Price : $50

At a glance

  • Originator Novartis
  • Class Antidepressants; Benzamides
  • Mechanism of Action Dopamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Major depressive disorder

Most Recent Events

  • 29 Sep 2000 No-Development-Reported for Depression in Switzerland (PO)
  • 29 Sep 2000 No-Development-Reported for Depression in Canada (PO)
  • 15 Aug 1996 Preclinical development for Depression in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top